Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Matthew S. Davids et al.|New England Journal of Medicine|2015Cited by 1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Mary Ann Anderson et al.|New England Journal of Medicine|2018Cited by 429
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Andrew W. Roberts, Jing Deng et al.|Blood|2016Cited by 329
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327